Skip to main content
SpringerLink
Log in

The effects of statins on high-density lipoproteins

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Statins inhibit cholesterol synthesis and are effective in lowering total cholesterol levels in plasma or serum due to reductions in low-density lipoprotein and very low-density lipoproteins, as well as reducing progression of coronary atherosclerosis, coronary heart disease, and stroke morbidity and mortality. These agents also modestly raise levels of high-density lipoprotein (HDL) cholesterol and its major protein, apolipoprotein (apo) A-I. The more effective statins can also raise the levels of large α-I HDL particles as assessed by two-dimensional gel electrophoresis. High levels of these particles promote reverse cholesterol transport and protect against coronary heart disease and progression of coronary atherosclerosis. The mechanism whereby statins alter HDL and its subspecies appears to be due to reduction of triglyceride-rich lipoproteins, with a secondary decrease in cholesteryl ester transfer protein activity, and less transfer of HDL cholesterol to triglyceride-rich lipoprotein acceptor particles. Increasingly, statins will be combined with other agents such as ezetimibe, fibrates, niacin, and cholesteryl ester transfer protein inhibitors to optimize the entire lipoprotein profile to alter not only low-density lipoprotein, but also HDL, triglycerides, lipoprotein(a), and C-reactive protein, and also to reduce cardiovascular morbidity and mortality.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Expert Panel: Third report of the Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol Levels in Adults (Adult Treatment Panel III). Bethesda, MD: NJH Publication 02-5215:1–284.

  2. Grundy SM, Cleeman JI, Merx NB, et al.: Implications of recent clinical trials for National Cholesterol Education Program Adult Treatment III Guidelines. Circulation 2004, 110:227–239.

    Article  PubMed  Google Scholar 

  3. Genest J, Frohlich J, Fodor G, McPherson R: Canadian dyslipidemia guidelines 2003. Can Med Asoc J 2003, 168:927–934.

    Google Scholar 

  4. DeBacker G, Ambrosioni E, Borch-Johnsen K, et al.: European guidelines for cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehab 2003, 10:S1-S10.

    Article  Google Scholar 

  5. Haffner SM: Dyslipidemia management in adults with diabetes. Diabetes Care 2003, 27:S68-S71.

    Google Scholar 

  6. Kastelein JJ, Isaacsohn JL, Ose L, et al.: Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol 2000, 86:221–223.

    Article  PubMed  CAS  Google Scholar 

  7. Ballantyne CM, Blazing MA, Hunninghake DB, et al.: Effect on high-density lipoprotein cholesterol of maximum doses of simvastatin and atorvastatin in patients with hypercholesterolemia: results of the comparative HDL efficacy and safety study (CHESS). Am Heart J 2003, 146:862–869.

    Article  PubMed  CAS  Google Scholar 

  8. Davidson M, Ma P, Stein EA, et al.: Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol 2002, 89:268–275.

    Article  PubMed  CAS  Google Scholar 

  9. Schwartz GG, Bolognese MA, Tremblay BP, et al.: Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. Am Heart J 2004, 148:e4-e8.

    Article  PubMed  Google Scholar 

  10. Jones PH, Davidson MH, Stein EA, et al.: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003, 92:152–160.

    Article  PubMed  CAS  Google Scholar 

  11. Jones PH, Hunninghake DB, Ferdinand KC, et al.: Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR Trial. Clin Ther 2004, 26:1388–1399.

    Article  PubMed  CAS  Google Scholar 

  12. McKenney JM, Jones PH, Adamczyk MA, et al.: Comparison of the efficacy of rosuvastatin versus atorvastatin, simvasatin, and pravastatin in achieving lipid goals: results from the STELAR trial. Curr Med Res Opin 2003, 19:689–698.

    Article  PubMed  CAS  Google Scholar 

  13. Deedwania PC, Hunninghake DB, Bays HE, et al.: Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. Am J Cardiol 2005, 95:360–366.

    Article  PubMed  CAS  Google Scholar 

  14. Schuster H, Barter PJ, Stender S, et al.: Effects of switching statins on achievement of lipid goals: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY I) study. Am Heart J 2004, 147:705–713.

    Article  PubMed  CAS  Google Scholar 

  15. Cheung RC, Morrell JM, Kallend D, et al.: Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study. Int J Cardiol 2005, 100:309–316.

    Article  PubMed  Google Scholar 

  16. Stender S, Schuster H, Barter P, et al.: Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolemic patients with and without the metabolic syndrome in the MERCURY I study. Diabetes Obesity Metab 2005, 7:430–438.

    Article  CAS  Google Scholar 

  17. Schneck DW, Knopp RH, Ballantyne CM, et al.: Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol 2002, 91:33–41.

    Article  Google Scholar 

  18. Yamamoto A, Arakawa K, Sasaki J, et al.: Clinical effects of rosuvastatin, a new HMG-CoA reductase inhibitor, in Japanese patients with primary hypercholesterolemia: an early phase II study. J Atheroscler Thromb 2002, 9:48–56.

    PubMed  CAS  Google Scholar 

  19. Javaram S, Jain MM, Naikawadi AA, et al.: Comparative evaluation of the efficacy, safety, and tolerability of rosuvastatin 10 mg with atorvastatin 10 mg in adult patients with hypercholesterolemia: the first Indian study. J Indian Med Assoc 2004, 102:48–50.

    Google Scholar 

  20. Saito Y, Goto Y, Dane A, et al.: Randomized dose-response study of rosuvastatin in Japanese patients with hypercolesterolemia. J Atheroscler Thromb 2003, 10:329–336.

    PubMed  CAS  Google Scholar 

  21. Stein EA, Strutt K, Southworth H, et al.: Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 2003, 92:1287–1293.

    Article  PubMed  CAS  Google Scholar 

  22. Mabuchi H, Nohara A, Higashikata T, et al.: Clinical efficacy and safety of rosuvastatin in Japanese patients with heterozygous familial hypercholesterolemia. J Atheroscler Thromb 2004, 11:152–158.

    PubMed  CAS  Google Scholar 

  23. Shepherd J, Packard C, Littlejohn TW, et al.: Lipid-modifying effects of rosuvastatin in post-menopausal women with hypercholesterolemia who are receiving hormonal therapy. Curr Med Res Opin 2004, 20:1571–1578.

    Article  PubMed  CAS  Google Scholar 

  24. Wolfenbuttel BH, Franken AA, Vincent HH, et al.: Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes—CORALL study. J Intern Med 2005, 257:531–539.

    Article  Google Scholar 

  25. Durrington PN, Tuomilehto J, Hamann A, et al.: Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combine hyperlipidaemia. Diabetes Res Clin Pract 2004, 64:137–151.

    Article  PubMed  CAS  Google Scholar 

  26. Lamendola C, Abbasi F, Chu JW, et al.: Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, non-diabetic patients with combined dyslipidemia. Am J Cardiol 2005, 95:189–193.

    Article  PubMed  CAS  Google Scholar 

  27. Capuzzi DM, Morgan JM, Carey CM, et al.: Rosuvastatin alone or with extended-release niacin: a new therapeutic option for patients with combined hyperlipidemia. Prev Cardiol 2004, 7:176–181.

    PubMed  CAS  Google Scholar 

  28. Kosoglou T, Statkevich P, Yang B, et al.: Pharmacodynamic interaction between ezetimibe and rosuvastatin. Curr Med Res Opin 2004, 20:1185–1195.

    Article  PubMed  CAS  Google Scholar 

  29. Asztalos BF, Cupples LA, Demissie S, et al.: High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2004, 24:2181–2187.

    Article  PubMed  CAS  Google Scholar 

  30. Asztalos BF, de la Llera-Moya M, Dallal GE, et al.: Differential effects of HDL subpopulations on cellular mediated ABCA1- and SRB1-mediated colesterol efflux. J Lipid Res 2005, In press.

  31. Asztalos BF, Collins D, Cupples LA, et al.: Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 2005, In press.

  32. Asztalos BF, Batista M, Horvath KV, et al.: Change in alpha 1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol 2003, 23:847–852.

    Article  PubMed  CAS  Google Scholar 

  33. Brousseau ME, Diffenderfer MR, Millar JS, et al.: Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol 2005, 25:1057–1064.

    Article  PubMed  CAS  Google Scholar 

  34. Schaefer EJ, McNamara JR, Tayler T, et al.: Effects of atorvastatin on fasting and post-prandial lipoprotein subclasses in coronary heart disease patients versus control subjects. Am J Cardiol 2002, 90:689–696.

    Article  PubMed  CAS  Google Scholar 

  35. Schaefer EJ, McNamara JR, Tayler T, et al.: Comparison of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and post-prandial lipoproteins in patients with coronary heart disease versus control subjects. Am J Cardiol 2004, 93:31–39.

    Article  PubMed  CAS  Google Scholar 

  36. Asztalos BF, Horvath KV, McNamara J, et al.: Effects of atorvastatin on HDL subpopyulations of coronary heart disease patients. J Lipid Res 2002, 43:1701–1707.

    Article  PubMed  CAS  Google Scholar 

  37. Asztalos BF, Horvath KV, McNamara JR, et al.: Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis 2002, 164:361–369.

    Article  PubMed  CAS  Google Scholar 

  38. Guerin M, Lassel TS, Le Goff, et al.: Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholestryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 2000, 20:189–197.

    PubMed  CAS  Google Scholar 

  39. Wilhelmsen I, Pyorala K, Wedel H, et al.: Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol lowering treatment. Eur Heart J 2001, 22:1065–1066.

    Article  Google Scholar 

  40. Ballantyne CM, Olsson AG, Cook TJ, et al.: Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease risk and response to simvastatin therapy in 4S. Circulation 2002, 104:3046–3051.

    Google Scholar 

  41. Gotto AM Jr, Whitney E, Stein EA, et al.: Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study. Circulation 2000, 101:477–484.

    PubMed  CAS  Google Scholar 

  42. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol with simvastatin in 20536 high risk individuals: a randomized placebo controlled trial. Lancet 2002, 360:7–22.

    Article  Google Scholar 

  43. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering in 5963 people with diabetes: a randomized placebo controlled trial. Lancet 2003, 361:2005–2016.

    Article  CAS  Google Scholar 

  44. Shepherd J, Blauw GJ, Murphy MB, et al.: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized trial. Lancet 2002, 360:1623–1630.

    Article  PubMed  CAS  Google Scholar 

  45. Sever PS, Dahlhof B, Poulter NR, et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149–1158.

    Article  PubMed  CAS  Google Scholar 

  46. Calhoun HM, Betteridge DJ, Durrington PN, et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): a multicentre randomised placebo controlled trial. Lancet 2004, 364:685–696.

    Article  CAS  Google Scholar 

  47. LaRosa JC, Grundy SM, Waters DD, et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 353:1425–1435.

    Article  Google Scholar 

  48. Wanner C, Krane V, Marz W, et al.: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353:238–248.

    Article  PubMed  CAS  Google Scholar 

  49. Ridker PM, Morrow DA, Rose LM, et al.: Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/I: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol 2005, 45:1644–1648.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiovascular Research Laboratory, Tufts University School of Medicine, 711 Washington Street, 02111, Boston, MA, USA

    Ernst J. Schaefer MD

Authors
  1. Ernst J. Schaefer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bela F. Asztalos PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ernst J. Schaefer MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schaefer, E.J., Asztalos, B.F. The effects of statins on high-density lipoproteins. Curr Atheroscler Rep 8, 41–49 (2006). https://doi.org/10.1007/s11883-006-0063-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-006-0063-3

Keywords

Search

Navigation